Open questions and evidence on new therapeutic standards for limited-stage diffuse large B-cell lymphomas
Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma, with limited-stage defined as stage I or II disease, having around 25-30% of newly diagnosed DLBCL this presentation. Risk stratification, initial treatment options, and relapse patterns are distinct from advanced-stage d...
Guardado en:
| Autor principal: | Mahuad , Carolina |
|---|---|
| Formato: | Artículo revista |
| Lenguaje: | Español |
| Publicado: |
Universidad Nacional de Rosario
2023
|
| Materias: | |
| Acceso en línea: | https://fcmcientifica.unr.edu.ar/index.php/revista/article/view/102 |
| Aporte de: |
Ejemplares similares
-
Diffuse primary cutaneous large B- cell lymphoma, leg type: case report
por: Villata , AC, et al.
Publicado: (2021) -
Central nervous system relapse in diffuse large B lymphoma: a retrospective cohort study: CNS relapse in LDCGB
por: Warley, Fernando, et al.
Publicado: (2021) -
Linfoma cutáneo de la zona marginal
por: Valenzuela, S, et al.
Publicado: (2025) -
Magnetic resonance as initial screening diagnosis of secondary involvement of central nervous system in NHL diffuse large B cell lymphoma
por: Oliver, Ana Carolina, et al.
Publicado: (2018) -
Progression of Chronic Lymphocytic Leukemia into Hodgkin Lymphoma during Ibrutinib treatment. Case Report
por: Heller , VB, et al.
Publicado: (2019)